Return On Equity
74%
Third-party reference; reporting period not verified
ELITE PHARMACEUTICALS INC /NV/ financial metrics
Period Q2 2026 · Filed 13 Aug 2026
Key metrics snapshot
Return On Assets
18%
Third-party reference; reporting period not verified
Operating Margin
23%
Third-party reference; reporting period not verified
Current Ratio
3.76x
Third-party reference; reporting period not verified
Quick Ratio
2.94x
Third-party reference; reporting period not verified
Debt-to-equity
0.05x
Third-party reference; reporting period not verified
Revenues YoY
34%
Trailing 12 months · Through 30 Jun 2026
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
74%
Third-party reference; reporting period not verified
|
|
| Return On Assets |
18%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
23%
Third-party reference; reporting period not verified
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
3.76x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
2.94x
Third-party reference; reporting period not verified
|
|
| Debt-to-equity |
0.05x
Third-party reference; reporting period not verified
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
34%
Trailing 12 months · 30 Jun 2026
|
|
| Net Income (Loss) Attributable to Parent |
$56,667,966
Trailing 12 months · 30 Jun 2026
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
1,077,196,442
Period-end balance · 27 Jun 2026
|
+0.82% |
| Common Stock, Shares, Outstanding |
1,077,136,442
Period-end balance · 30 Jun 2026
|
+0.82% |
| Common Stock, Value, Issued |
$1,077,240
Period-end balance · 30 Jun 2026
|
+0.82% |
| Weighted Average Number of Shares Outstanding, Basic |
1,077,236,002
Reported period · 30 Jun 2026
|
+0.83% |
| Weighted Average Number of Shares Outstanding, Diluted |
1,128,661,497
Reported period · 30 Jun 2026
|
+5.6% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$5,591,368
Period-end balance · 30 Jun 2026
|
+9.9% |
| Accounts Receivable, after Allowance for Credit Loss, Current |
$50,441,624
Period-end balance · 30 Jun 2026
|
+39% |
| Accrued Liabilities, Current |
$6,429,800
Period-end balance · 30 Jun 2026
|
+40% |
| Additional Paid in Capital |
$173,976,332
Period-end balance · 30 Jun 2026
|
+0.27% |
| Assets |
$139,669,132
Period-end balance · 30 Jun 2026
|
+25% |
| Assets, Current |
$114,487,702
Period-end balance · 30 Jun 2026
|
+47% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$39,415,579
Period-end balance · 30 Jun 2026
|
+78% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$9,146,259
Reported period · 30 Jun 2026
|
-12% |
| Common Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 30 Jun 2026
|
0% |
| Common Stock, Shares Authorized |
1,445,000,000
Period-end balance · 30 Jun 2026
|
0% |
| Common Stock, Shares, Issued |
1,077,236,442
Period-end balance · 30 Jun 2026
|
+0.82% |
| Cost of Revenue |
$79,708,395
Trailing 12 months · 30 Jun 2026
|
+71% |
| Deferred Income Tax Assets, Net |
$6,501,308
Period-end balance · 30 Jun 2026
|
-52% |
| Deferred Income Tax Expense (Benefit) |
$1,321,731
Reported period · 30 Jun 2026
|
-73% |
| Depreciation |
$252,975
Reported period · 30 Jun 2026
|
-8.1% |
| Depreciation, Depletion and Amortization |
$1,049,105
Trailing 12 months · 30 Jun 2026
|
-11% |
| Earnings Per Share, Basic |
0.06
Trailing 12 months · 30 Jun 2026
|
|
| Earnings Per Share, Diluted |
0.05
Trailing 12 months · 30 Jun 2026
|
|
| General and Administrative Expense |
$17,742,275
Trailing 12 months · 30 Jun 2026
|
+70% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
$65,095,240
Trailing 12 months · 30 Jun 2026
|
|
| Income Tax Expense (Benefit) |
$8,427,274
Trailing 12 months · 30 Jun 2026
|
-9.9% |
| Increase (Decrease) in Accounts Receivable |
$9,435,545
Reported period · 30 Jun 2026
|
-231% |
| Interest Paid, Excluding Capitalized Interest, Operating Activities |
$27,170
Reported period · 30 Jun 2026
|
-83% |
| Inventory, Net |
$24,200,388
Period-end balance · 30 Jun 2026
|
+25% |
| Lessee, Operating Lease, Liability, to be Paid |
$1,608,089
Period-end balance · 30 Jun 2026
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$440,159
Period-end balance · 30 Jun 2026
|
-34% |
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$666,207
Period-end balance · 30 Jun 2026
|
-0.16% |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$183,969
Period-end balance · 30 Jun 2026
|
-48% |
| Liabilities |
$34,843,076
Period-end balance · 30 Jun 2026
|
-45% |
| Liabilities and Equity |
$139,669,132
Period-end balance · 30 Jun 2026
|
+25% |
| Liabilities, Current |
$30,441,614
Period-end balance · 30 Jun 2026
|
+183% |
| Net Cash Provided by (Used in) Financing Activities |
$114,594
Reported period · 30 Jun 2026
|
+97% |
| Net Cash Provided by (Used in) Investing Activities |
$808,964
Reported period · 30 Jun 2026
|
-271% |
| Net Cash Provided by (Used in) Operating Activities |
$10,069,817
Reported period · 30 Jun 2026
|
-32% |
| Nonoperating Income (Expense) |
$30,152,482
Trailing 12 months · 30 Jun 2026
|
|
| Operating Income (Loss) |
$34,942,758
Trailing 12 months · 30 Jun 2026
|
-6.7% |
| Operating Lease, Liability |
$1,424,120
Period-end balance · 30 Jun 2026
|
-26% |
| Operating Lease, Liability, Current |
$553,534
Period-end balance · 30 Jun 2026
|
+13% |
| Operating Lease, Liability, Noncurrent |
$870,586
Period-end balance · 30 Jun 2026
|
-39% |
| Operating Lease, Right-of-Use Asset |
$1,404,216
Period-end balance · 30 Jun 2026
|
-26% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.1
Period-end balance · 30 Jun 2026
|
0% |
| Payments to Acquire Property, Plant, and Equipment |
$808,964
Reported period · 30 Jun 2026
|
+271% |
| Property, Plant and Equipment, Gross |
$29,090,535
Period-end balance · 30 Jun 2026
|
+5.5% |
| Property, Plant and Equipment, Net |
$10,737,317
Period-end balance · 30 Jun 2026
|
+4.6% |
| Research and Development Expense |
$6,100,462
Trailing 12 months · 30 Jun 2026
|
-18% |
| Retained Earnings (Accumulated Deficit) |
$69,920,675
Period-end balance · 30 Jun 2026
|
+45% |
| Revenue from Contract with Customer, Excluding Assessed Tax |
$141,014,305
Trailing 12 months · 30 Jun 2026
|
+34% |
| Share-based Payment Arrangement, Expense |
$152,654
Trailing 12 months · 30 Jun 2026
|
-33% |
| Stockholders' Equity Attributable to Parent |
$104,826,056
Period-end balance · 30 Jun 2026
|
+120% |
Comparisons, sources and research notes
Sources and sharing
ELTP - ELITE PHARMACEUTICALS INC /NV/ Financial Facts
- Context
- Latest metrics period: Q2 2026
- Latest reported value
- Return On Equity 74%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q2 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q2 2026.
- Most recent SEC facts end date on this page: 30 Jun 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for ELTP - ELITE PHARMACEUTICALS INC /NV/
Latest financial period: Q2 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
13 Aug 2026
Page type
Company facts
Latest period
Q2 2026
SEC-backed company facts were refreshed from filings filed on 13 Aug 2026.
Benchmark Context
How Return On Equity compares
Return On Equity does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with ELITE PHARMACEUTICALS INC /NV/'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q2 2026.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Filing notes and source
Key facts
- ELTP - ELITE PHARMACEUTICALS INC /NV/ financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q2 2026.
- Headline metric: Return On Equity 74%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 30 Jun 2026.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-06-30) highlights Return On Equity 74.3%, Return On Assets 17.8%, and Operating Margin 23.3%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Medium confidence
-28%
fair value gap
Fair value per share
$0.2595
Market price
$0.3600
ELTP - Local security
PEG ratio
0.2x
P/E 7.2x / growth 37%
EPS CAGR (3Y)
Enterprise value
$255.23M
Equity value
$292.89M
DCF fair value scenarios
Bear
$0.2021
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -44%
Base
$0.2595
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -28%
Bull
$0.3498
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -2.8%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
2.6x
Local security market EV / SEC revenue
EV/EBITDA
10.2x
Local security market EV / SEC EBITDA
P/E
7.2x
Local security market price / SEC EPS
P/S
2.9x
Local security market cap / SEC revenue
P/B
3.9x
Local security market cap / SEC equity
PEG
0.2x
P/E / EPS CAGR
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $17.53M
- Trailing SEC FCF
- Reported FCF
- $17.53M
- Net income
- $56.67M
- EBITDA
- $35.99M
- Cash
- $38.94M
- Debt
- $1.28M
- Equity
- $104.83M
- Shares
- 1,128,661,497
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf uses fallback growth assumption because historical free cash flow growth is unavailable
Compare This Company Through SEC-backed Metrics
Use these links to compare ELTP - ELITE PHARMACEUTICALS INC /NV/ against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: 34%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
85.8/100
Strong Confidence medium
Return On Equity
74%
Metric score 100.0/100
Return On Assets
18%
Metric score 100.0/100
Financial Health
- Current Ratio
- 3.76x
- Quick Ratio
- 2.94x
- Debt to Equity
- 0.05x
Strengths
Return On Equity, Return On Assets, and Operating Margin
Watchpoints
No major risk flags from available metrics.
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first